DB:ORN

Stock Analysis Report

Executive Summary

Oryzon Genomics S.A., a clinical stage biopharmaceutical company, discovers and develops epigenetics-based therapeutics to treat oncology and neurodegenerative diseases.


Snowflake Analysis

Flawless balance sheet with limited growth.

Share Price & News

How has Oryzon Genomics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ORN has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

3.2%

ORN

-4.3%

DE Biotechs

-4.7%

DE Market


1 Year Return

-16.6%

ORN

5.5%

DE Biotechs

8.3%

DE Market

Return vs Industry: ORN underperformed the German Biotechs industry which returned 5.5% over the past year.

Return vs Market: ORN underperformed the German Market which returned 8.3% over the past year.


Shareholder returns

ORNIndustryMarket
7 Day3.2%-4.3%-4.7%
30 Day-7.1%-6.7%-4.0%
90 Day15.6%0.4%-1.4%
1 Year-16.6%-16.6%5.8%5.5%11.7%8.3%
3 Yearn/a40.9%39.4%11.4%1.6%
5 Yearn/a10.9%8.6%15.1%-0.7%

Price Volatility Vs. Market

How volatile is Oryzon Genomics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Oryzon Genomics undervalued compared to its fair value and its price relative to the market?

1.86x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ORN's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ORN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ORN is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: ORN is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ORN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ORN is good value based on its PB Ratio (1.9x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is Oryzon Genomics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

-19.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ORN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ORN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ORN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ORN's revenue (55.8% per year) is forecast to grow faster than the German market (5.1% per year).

High Growth Revenue: ORN's revenue (55.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ORN's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Oryzon Genomics performed over the past 5 years?

-30.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ORN is currently unprofitable.

Growing Profit Margin: ORN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ORN is unprofitable, and losses have increased over the past 5 years at a rate of -30.2% per year.

Accelerating Growth: Unable to compare ORN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ORN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: ORN has a negative Return on Equity (-5.63%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Oryzon Genomics's financial position?


Financial Position Analysis

Short Term Liabilities: ORN's short term assets (€41.3M) exceed its short term liabilities (€10.5M).

Long Term Liabilities: ORN's short term assets (€41.3M) exceed its long term liabilities (€7.9M).


Debt to Equity History and Analysis

Debt Level: ORN's debt to equity ratio (21.3%) is considered satisfactory.

Reducing Debt: ORN's debt to equity ratio has reduced from 68.2% to 21.3% over the past 5 years.


Balance Sheet

Inventory Level: ORN has a low level of unsold assets or inventory.

Debt Coverage by Assets: ORN's debt is covered by short term assets (assets are 3.1x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ORN has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: ORN has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -44.4% each year


Next Steps

Dividend

What is Oryzon Genomics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.0%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate ORN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ORN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ORN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ORN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ORN's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.6yrs

Average management tenure


CEO

Carlos Manuel Buesa Arjol 0

19.1yrs

Tenure

€58,000

Compensation

Mr. Carlos Buesa Arjol Co-Founded Oryzon Genomics S.A. in 2000 and has been its Chairman and Chief Executive Officer since 2001 and serves as its President and served as its Member of Financial Advisory Bo ...


CEO Compensation Analysis

Compensation vs Market: Carlos Manuel's total compensation ($USD0.00) is below average for companies of similar size in the German market ($USD414.81K).

Compensation vs Earnings: Carlos Manuel's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Carlos Manuel Buesa Arjol
Co-Founder19.1yrs€58.00k8.27% 11.2m
Tamara Maes
First Deputy President & Chief Scientific Officer0yrs€58.00k8.23% 11.1m
Enric Rello
COO & CFO of Spain0yrsno datano data
Anna Baran-Djokovic
Investor Relations Director0yrsno datano data
Emili Torrell
Chief Business Development Officer0yrsno datano data
Neus Virgili
Chief Intellectual Property Officer8.4yrsno datano data
Cesar Molinero
Chief Clinical Officer2.8yrsno datano data
Roger Bullock
Chief Medical Officer2.8yrsno datano data
Sonia Gutierrez
Chief of Clinical Operations0yrsno datano data
Augusto Pinel Rubio
Secretary0yrsno datano data

5.6yrs

Average Tenure

Experienced Management: ORN's management team is seasoned and experienced (5.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Carlos Manuel Buesa Arjol
Co-Founder19.1yrs€58.00k8.27% 11.2m
Tamara Maes
First Deputy President & Chief Scientific Officer0yrs€58.00k8.23% 11.1m
Isabel Aguilera Navarro
Independent Director4.3yrs€7.00kno data
Carlos López-Casas
Member of Financial Advisory Board0yrsno datano data
Lori Kunkel
Member of Scientific Advisory Board2yrsno datano data
Josep María Echarri Torres
Director0yrs€6.00k2.3% 3.1m
Ramon Adell Ramon
Independent Director4.3yrs€7.00k0.044% 59.4k
Leon Hooftman
Member of Scientific Advisory Board0yrsno datano data
Antonio Fornieles Melero
Lead Independent Director4.3yrs€7.00kno data
Felipe Prósper Cardoso
Member of Scientific Advisory Board0yrsno datano data

4.3yrs

Average Tenure

60yo

Average Age

Experienced Board: ORN's board of directors are considered experienced (4.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.4%.


Top Shareholders

Company Information

Oryzon Genomics S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Oryzon Genomics S.A.
  • Ticker: ORN
  • Exchange: DB
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €135.101m
  • Shares outstanding: 45.49m
  • Website: https://www.oryzon.com

Number of Employees


Location

  • Oryzon Genomics S.A.
  • Sant Ferran 74
  • Cornellà de Llobregat
  • Barcelona
  • Catalonia
  • 8940
  • Spain

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ORYBME (Bolsas y Mercados Espanoles)YesCommon SharesESEURDec 2015
0RDBLSE (London Stock Exchange)YesCommon SharesGBEURDec 2015
ORNDB (Deutsche Boerse AG)YesCommon SharesDEEURDec 2015
ORYEBATS-CHIXE (BATS 'Chi-X Europe')YesCommon SharesGBEURDec 2015

Biography

Oryzon Genomics S.A., a clinical stage biopharmaceutical company, discovers and develops epigenetics-based therapeutics to treat oncology and neurodegenerative diseases. Its clinical-stage product candidates include ORY-1001, an oncology product, which is in Phase IIA clinical trial for treating acute leukemia and small cell lung cancer; and ORY-2001, a dual LSD1 and MAO-B inhibitor that is in Phase IIA clinical trial for Alzheimer’s disease and multiple sclerosis. The company is also developing ORY-3001, a selective LSD1 inhibitor that is in preclinical stage for the treatment of non-oncological diseases; and other programs. Oryzon Genomics S.A. was founded in 2000 and is based in Barcelona, Spain. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/24 23:30
End of Day Share Price2020/02/24 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.